Introduction {#H1-1-ZOI200166}
============

Visual impairment (VI), defined as low vision or blindness, affects approximately 441.1 million individuals, disproportionately affecting individuals 50 years and older.^[@zoi200166r1]^ With the rapidly aging populations,^[@zoi200166r2]^ the prevalence of VI is expected to increase 3-fold by 2050.^[@zoi200166r1]^ VI imposes a substantial health burden in terms of quality-adjusted life-years or years lived with disability that is comparable to major chronic diseases, such as diabetes, dyslipidemia, cardiovascular diseases (CVD), and obesity.^[@zoi200166r3],[@zoi200166r4]^ Likewise, deficits in cognitive function are also a major cause of morbidity.^[@zoi200166r4]^ Previous studies^[@zoi200166r5],[@zoi200166r6],[@zoi200166r7]^ have found a close association between VI and decline in cognitive function.

It has been postulated that visually impaired individuals have more difficulties in performing daily activities, such as reading and seeing faces.^[@zoi200166r8]^ Reduced engagement in these cognitively stimulating activities may lead to brain reserve deficits, resulting in decline in cognitive function.^[@zoi200166r9],[@zoi200166r10],[@zoi200166r11],[@zoi200166r12],[@zoi200166r13]^ In this regard, several cross-sectional studies^[@zoi200166r12],[@zoi200166r14],[@zoi200166r15],[@zoi200166r16],[@zoi200166r17]^ found a significant association between VI and decline in cognitive function. However, longitudinal reports^[@zoi200166r5],[@zoi200166r6],[@zoi200166r7],[@zoi200166r18]^ in this area are currently scarce and nonconclusive. Furthermore, to our knowledge, no longitudinal studies have investigated the association between VI and cognitive decline in Asian populations.

The objective of this study was to determine the longitudinal association between VI and cognitive decline over time in a multiethnic, elderly Asian population. Findings from this study are intended to help better identify elderly Asian individuals who may be at higher risk of cognitive decline.

Methods {#H1-2-ZOI200166}
=======

Study Population {#H2-1-ZOI200166}
----------------

We conducted a prospective, population-based cohort study using individuals recruited from the Singapore Epidemiology of Eye Diseases (SEED) study, which was composed of 3 major Asian ethnic groups in Singapore. At baseline, participants from SEED were recruited under 3 studies: the Singapore Malay Eye Study (SiMES; 2004-2006), the Singapore Indian Eye Study (SINDI; 2007-2009), and the Singapore Chinese Eye Study (SCES; 2009-2011). All study procedures were performed in accordance with the principles of the Declaration of Helsinki,^[@zoi200166r19]^ and ethical approval was obtained from the Singapore Eye Research Institute Institutional Review Board. Written informed consent was obtained from all study participants. Data were deidentified before the analysis was performed. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.^[@zoi200166r20]^

In brief, an age-stratified random sampling was used to select Malay, Indian, and Chinese adults aged 40 to 80 years. A total of 4168 Malay, 4497 Indian, and 4606 Chinese adults were randomly selected, of whom a total of 10 033 individuals (3280 Malay, 3400 Indian, and 3353 Chinese adults) participated in the study, with an overall response rate of 75.6%.

Follow-up examination of the SEED study was conducted 6 years later (2011-2013 for SiMES, 2013-2015 for SINDI, and 2015-2017 for SCES). The methods of the initial and follow-up SEED studies have been described in detail previously.^[@zoi200166r21],[@zoi200166r22],[@zoi200166r23],[@zoi200166r24]^

In the baseline examination, cognitive assessment by the Abbreviated Mental Test (AMT) was performed only among participants 60 years or older (n = 4407). Participants with missing baseline AMT data (n = 97) or missing baseline visual acuity (VA) data (n = 1) were excluded. Of the remaining 4309 individuals from baseline, 1134 were ineligible for follow-up in the SEED study because of death (n = 652), migration or relocation (n = 113), and severe illness or severe mobility impairment (n = 369). Of the 3175 participants eligible for follow-up, 688 did not attend the follow-up examination. Consequently, 2487 individuals were reexamined on follow-up. Of these individuals, 9 did not complete the AMT, thereby leaving 2478 participants included in the final analysis (response rate, 78.0% \[2478 of 3175\]) ([Figure](#zoi200166f1){ref-type="fig"}).

![Flowchart for Inclusion and Exclusion of Study Participants\
AMT indicates Abbreviated Mental Test; SEED, Singapore Epidemiology of Eye Diseases.](jamanetwopen-3-e203560-g001){#zoi200166f1}

Vision Assessment {#H2-2-ZOI200166}
-----------------

Presenting distance VA data were collected for both eyes. VA was measured at 4 m using the logMAR number chart (Lighthouse International). If the largest print of numbers could not be read at 4 m, the individuals were subsequently positioned at 3, 2, and 1 m. If no numbers were read correctly from the chart, VA was measured and recorded as counting fingers, hand movement, light perception, or no light perception accordingly. For presenting VA, participants were instructed to wear their own prescriptive correction, if any.

In this study, VI was based on the US definition.^[@zoi200166r25]^ Any VI was defined as presenting VA worse than 20/40. Low vision was defined as presenting VA worse than 20/40 but better than 20/200, whereas blindness was defined as presenting VA worse than or equivalent to 20/200.

Assessment of Cognitive Function {#H2-3-ZOI200166}
--------------------------------

We assessed cognitive performance using the AMT (eFigure in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}), a 10-question abbreviated questionnaire derived from the 26-question Roth-Hopkins test.^[@zoi200166r26],[@zoi200166r27]^ The version of the AMT questionnaire used was slightly modified for the Singapore context^[@zoi200166r28]^ and had been validated in several population-based studies.^[@zoi200166r16],[@zoi200166r29],[@zoi200166r30],[@zoi200166r31],[@zoi200166r32],[@zoi200166r33],[@zoi200166r34]^ The AMT was administered by trained study investigators to participants 60 years or older in a language of their preference. All questions were of equal weight (1 mark each), culminating in a total possible score of 10. Change in AMT score over time was calculated as the AMT score at 6-year follow-up minus the AMT score at the baseline visit. A negative difference denotes a decrease in AMT score.

Other Measurements and Systemic Assessments {#H2-4-ZOI200166}
-------------------------------------------

For all participants at the baseline visit, we used interviewer-administered questionnaires to ascertain information about their demographic characteristics, lifestyle risk factors (ie, current smoking status and alcohol intake), and medical history. Educational level was categorized as no formal education; primary education; O levels or equivalent; A levels, polytechnic, diploma, or technical school equivalent; or university education. Diabetes was defined as a random glucose level of 200 mg/dL or higher (to convert to millimoles per liter, multiply by 0.0555), glycated hemoglobin level of 6.5% of total hemoglobin or greater (to convert to proportion of hemoglobin, multiply by 0.01), current use of diabetes medication, or self-reported history of diabetes. Hyperlipidemia was defined as a total cholesterol level of 239 mg/dL or higher (to convert to millimoles per liter, multiply by 0.0259) or current use of lipid-lowering medication. Hypertension was defined as systolic blood pressure of 140 mm Hg or higher, diastolic blood pressure of 90 mm Hg or higher, current use of blood pressure medication, or self-reported history of hypertension. Chronic kidney disease (CKD) was defined as estimated glomerular filtration rate less than 60 mL/min/1.73 m^2^ based on the Chronic Kidney Disease Epidemiology Collaboration equation.^[@zoi200166r35]^ History of CVD was defined based on self-reported history of angina, stroke, or myocardial infarction. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared and categorized as underweight (\<18.5), healthy weight (≥18.5 to \<25), overweight (≥25 to \<30), or obese (≥30).

Statistical Analysis {#H2-5-ZOI200166}
--------------------

All statistical analyses were performed using Stata statistical software, version 13 (StataCorp LLC). Statistical significance was determined as *P* \< .05 based on a 2-sided evaluation. Age, BMI, and AMT scores at baseline were analyzed as continuous variables, whereas sex; race/ethnicity; presence of diabetes, hyperlipidemia, hypertension, and CKD; history of CVD; alcohol intake; current smoking status; educational status; and VI were analyzed as categorical variables. We performed an independent, 2-tailed, unpaired *t* test for continuous data and Pearson χ^2^ test for categorical data to compare between individuals included and excluded in our final analysis and between individuals with and without presenting VI at baseline (based on better eye). In addition, we also compared baseline VI status between individuals with and without a decrease in AMT score over time.

A multivariable linear regression model was used to ascertain the associations between baseline presenting VA and VI with change in AMT score over 6 years. Model 1 was adjusted for baseline age, sex, and race/ethnicity, whereas model 2 was further adjusted for baseline presence of diabetes, hyperlipidemia, hypertension, and CKD; history of CVD; current smoking status; alcohol intake; BMI; educational status; and AMT score. Multivariable linear regression was performed separately for different baseline VI statuses: (1) VI based on better eye and (2) VI based on worse eye. For finer analysis of severity, VI was further categorized into low vision and blindness. Association between change in vision status (over 6 years) and change in AMT score was also evaluated. Sensitivity analyses excluding items 8 and 10 from the aggregate score of AMT were conducted for the associations between baseline vision and change in vision status with change in AMT score. We further evaluated the main causes of VI among individuals with baseline VI and a substantial decrease in AMT score of 3 units or more over the 6-year follow-up period. Data analysis was performed from November 1 to 24, 2019.

Results {#H1-3-ZOI200166}
=======

A total of 2478 individuals (1256 \[50.7%\] male; 1073 Chinese, 768 Indian, and 637 Malay adults) with a mean (SD) age of 67.6 (5.6) years were included in the final analysis. Those included for analysis had a mean (SD) follow-up period of 6.2 (0.9) years. In comparison, excluded individuals were older, more likely to be Malay, and more likely to have VI (based on better eye), lower AMT scores, no formal education, diabetes, hypertension, history of CVD, CKD, and current smoking status at baseline (eTable 1 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}). Of the included individuals, 726 had VI at baseline (based on better eye). Compared with individuals without VI at baseline, those with VI at baseline were more likely to be older, female, and Malay; more likely to have lower AMT scores, no formal education, and CKD; and less likely to have alcohol intake at baseline (eTable 2 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}).

Of the 2478 included individuals, 489 (19.7%) had decreases in AMT scores over 6 years and 1989 did not. Compared with those without decreases in AMT scores over 6 years (542 \[27.3%\] based on better eye and 1118 \[56.2%\] based on worse eye; *P* \< .001), individuals with decreases in AMT scores were more likely to have VI at baseline (184 \[37.6%\] based on better eye and 324 \[66.3%\] based on worse eye; *P* \< .001).

[Table 1](#zoi200166t1){ref-type="table"} details the association between baseline vision status and change in AMT score. After baseline age; sex; race/ethnicity; presence of diabetes, hyperlipidemia, hypertension, and CKD; history of CVD; current smoking status; alcohol intake; BMI; educational status; and AMT scores were adjusted for, poorer VA level at baseline was associated with decreases in AMT scores over 6 years (per 0.1 logMAR VA less; β = −0.07; 95% CI, −0.09 to −0.05; *P* \< .001 based on the better eye; β = −0.03; 95% CI, −0.04 to −0.02; *P* \< .001 based on the worse eye). After adjusting for the same set of covariates, VI at baseline was associated with decreases in AMT scores (β = −0.27; 95% CI, −0.37 to −0.17; *P* \< .001 based on the better eye; β = −0.16; 95% CI, −0.26 to −0.07; *P* = .001 based on the worse eye). When further evaluating severity of VI based on the better eye, low vision (β = −0.25; 95% CI, −0.35 to −0.14; *P* \< .001) and blindness (β = −1.07; 95% CI, −1.50 to −0.64; *P* \< .001) at baseline were significantly associated with decreases in AMT scores compared with normal vision. This finding was similarly observed when evaluating severity of baseline VI based on the worse eye, albeit with slightly smaller effect estimates. In further sensitivity analyses that excluded AMT items 8 and 10 from the aggregate score of AMT, we still observed largely similar associations as the original analyses (eTable 3 and eTable 4 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}).

###### Association Between Baseline Vision Status and Change in Abbreviated Mental Test Score

  Baseline vision status[^a^](#zoi200166t1n1){ref-type="table-fn"}        Model 1[^b^](#zoi200166t1n2){ref-type="table-fn"}   Model 2[^c^](#zoi200166t1n3){ref-type="table-fn"}                            
  ----------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ------------------------ --------
  **Based on better eye**[^**e**^](#zoi200166t1n5){ref-type="table-fn"}                                                                                                                                    
  Presenting VA level (per 0.1 logMAR unit)                               0.00 (−0.02 to 0.02)                                .79                                                 −0.07 (−0.09 to −0.05)   \<.001
  Visual impairment                                                                                                                                                                                        
  None                                                                    1 \[Reference\]                                     NA                                                  1 \[Reference\]          NA
  Any                                                                     0.01 (−0.10 to 0.12)                                .87                                                 −0.27 (−0.37 to −0.17)   \<.001
  Vision                                                                                                                                                                                                   
  Normal                                                                  1 \[Reference\]                                     NA                                                  1 \[Reference\]          NA
  Low                                                                     0.02 (−0.10 to 0.13)                                .79                                                 −0.25 (−0.35 to −0.14)   \<.001
  Blind                                                                   −0.15 (−0.61 to 0.31)                               .52                                                 −1.07 (−1.50 to −0.64)   \<.001
  **Based on worse eye**[^**f**^](#zoi200166t1n6){ref-type="table-fn"}                                                                                                                                     
  Presenting VA level (per 0.1 logMAR unit)                               0.00 (−0.01 to 0.01)                                .52                                                 −0.03 (−0.04 to −0.02)   \<.001
  Visual impairment                                                                                                                                                                                        
  None                                                                    1 \[Reference\]                                     NA                                                  1 \[Reference\]          NA
  Any                                                                     0.00 (−0.10 to 0.10)                                \>.99                                               −0.16 (−0.26 to −0.07)   .001
  Vision                                                                                                                                                                                                   
  Normal                                                                  1 \[Reference\]                                     NA                                                  1 \[Reference\]          NA
  Low                                                                     0.01 (−0.10 to 0.12)                                .84                                                 −0.13 (−0.23 to −0.03)   .008
  Blind                                                                   −0.07 (−0.27 to 0.12)                               .45                                                 −0.41 (−0.59 to −0.23)   \<.001

Abbreviations: NA, not applicable; VA, visual acuity.

Based on US definition: any visual impairment was defined as presenting VA worse than 20/40, low vision was defined as presenting VA worse than 20/40 but better than 20/200, and blindness was defined as presenting VA of 20/200 or worse.

Adjusted for baseline age, sex, and race/ethnicity.

Adjusted for baseline age; sex; race/ethnicity; presence of diabetes, hyperlipidemia, hypertension, cardiovascular disease, and chronic kidney disease; current smoking status; alcohol intake; body mass index; educational status; and Abbreviated Mental Test score.

β Denotes the change in Abbreviated Mental Test score per unit change in exposure variables.

Includes cases of bilateral low vision, bilateral blindness, and blindness in one eye with low vision in fellow eye.

Includes cases of unilateral low vision, bilateral low vision, unilateral blindness, bilateral blindness, and blindness in one eye with low vision in fellow eye.

[Table 2](#zoi200166t2){ref-type="table"} details the association between change in vision status (over 6 years) and change in AMT score. After baseline age, sex; race/ethnicity; presence of diabetes, hyperlipidemia, hypertension, and CKD; history of CVD; current smoking status; alcohol intake; BMI; educational status; and AMT score were adjusted for, unchanged or deteriorated VI over time (based on the better eye) were associated with decreases in AMT scores (β = −0.29; 95% CI, −0.40 to −0.18; *P* \< .001). Evaluation based on the worse eye demonstrated a similar association (β = −0.20; 95% CI, −0.29 to −0.10; *P* \< .001). In further sensitivity analyses that excluded AMT items 8 and 10 from the aggregate score of AMT, we still observed largely similar associations as in the original analyses (eTable 5 and eTable 6 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}).

###### Association Between Change in Vision Status Over 6 Years and Change in Abbreviated Mental Test Score

  Change in vision status over 6 y                                           Model 1[^a^](#zoi200166t2n1){ref-type="table-fn"}   Model 2[^b^](#zoi200166t2n2){ref-type="table-fn"}                            
  -------------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ------------------------ --------
  **Based on better eye**                                                                                                                                                                                     
  Remained or improved to normal vision                                      1 \[Reference\]                                     NA                                                  1 \[Reference\]          NA
  Remained or deteriorated to VI[^d^](#zoi200166t2n4){ref-type="table-fn"}   −0.12 (−0.24 to 0.00)                               .051                                                −0.29 (−0.40 to −0.18)   \<.001
  **Based on worse eye**                                                                                                                                                                                      
  Remained or improved to normal vision                                      1 \[Reference\]                                     NA                                                  1 \[Reference\]          NA
  Remained or deteriorated to VI[^d^](#zoi200166t2n4){ref-type="table-fn"}   −0.05 (−0.15 to 0.06)                               .38                                                 −0.20 (−0.29 to −0.10)   \<.001

Abbreviations: NA, not applicable; VI, visual impairment.

Adjusted for baseline age, sex, and ethnicity.

Adjusted for baseline age; sex; race/ethnicity; presence of diabetes, hyperlipidemia, hypertension, cardiovascular disease, and chronic kidney disease; current smoking status; alcohol intake; body mass index; educational status; and Abbreviated Mental Test score.

β Denotes the change in Abbreviated Mental Test score per unit change in exposure variables.

Based on US definition: VI was defined as presenting visual acuity worse than 20/40.

[Table 3](#zoi200166t3){ref-type="table"} details the main causes of VI among individuals with baseline VI and a substantial decrease in AMT score of at least 3 units over 6 years. On the basis of the better eye, the leading causes of VI were undercorrected refractive error (14 \[45.2%\]) and cataract (11 \[35.5%\]). Similarly, on the basis of the worse eye, undercorrected refractive error (26 \[51%\]) and cataract (15 \[29.4%\]) were the leading causes.

###### Main Causes of VI Among Individuals With Baseline VI and Substantial Decrease in AMT Score Over 6 Years

  Causes of VI                       Participants with baseline VI and decrease in AMT score ≥3 units, No. (%)   
  ---------------------------------- --------------------------------------------------------------------------- -----------
  Undercorrected refractive error    14 (45.2)                                                                   26 (51.0)
  Cataract                           11 (35.5)                                                                   15 (29.4)
  Diabetic retinopathy               2 (6.5)                                                                     2 (3.9)
  Posterior capsular opacification   1 (3.2)                                                                     1 (2.0)
  Pterygium                          1 (3.2)                                                                     1 (2.0)
  Optic atrophy                      1 (3.2)                                                                     0
  Age-related macular degeneration   0                                                                           2 (3.9)
  Corneal scar                       0                                                                           1 (2.0)
  Macular hole                       0                                                                           1 (2.0)
  Retinal vein occlusion             0                                                                           1 (2.0)
  Myopic maculopathy                 0                                                                           1 (2.0)
  Others                             1 (3.2)                                                                     0

Abbreviations: AMT, Abbreviated Mental Test; VI, visual impairment.

Of the 10 items in the AMT (eFigure in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}), item 8 is a vision-related task and required participants to identify the occupation of a person depicted in a picture. Thus, the participant's response to this item may be particularly sensitive to VI and potentially inflate the originally observed association between VI and cognitive decline. Furthermore, we also evaluated the partial correlation of each AMT item with presenting VA level (eTable 7 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}) and observed that the association was slightly higher in item 8 compared with most of the other AMT items, although the effect sizes of correlation for all items were generally small. Nevertheless, to rule out this potential bias, we further performed sensitivity analyses that excluded item 8 from the aggregate AMT score (eTable 3 and eTable 5 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}). The sensitivity analyses demonstrated similar associations as in the original analyses.

It is also possible that participants' educational level may affect the responses of certain items in the AMT. Thus, we further evaluated the partial correlation of each AMT item with educational level (eTable 8 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}) and observed that the association was noticeably higher in item 10, which involved memorizing a short phrase. Although educational level was adjusted in our multivariable models, there might still be a residual confounding effect. Furthermore, item 10 had the highest incorrect response rate compared with other items among individuals with VI (eTable 9 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}). Thus, to rule out that the originally observed finding was not associated with item 10 per se, we also performed another series of sensitivity analyses excluding item 10 from the aggregate AMT score (eTable 4 and eTable 6 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}). All trends and associations remained consistently similar in these sensitivity analyses.

Because hearing loss and dual sensory loss (hearing impairment and VI) had been reported to be associated with decline in cognitive function,^[@zoi200166r6],[@zoi200166r36],[@zoi200166r37]^ we also evaluated the association of self-reported hearing loss at baseline with decline in cognitive function in our study. Nevertheless, we did not find a significant association. We were not able to further perform interaction analysis between baseline hearing loss and VI with decline in cognitive function because of suboptimal model fitting as a result of a limited number of participants with hearing loss. In addition, apart from VI, among the adjusted covariates, age (per year; β = −0.04; 95% CI, −0.04 to −0.03); female sex (β = −0.18; 95% CI, −0.29 to −0.08); Chinese race/ethnicity (β = 0.39; 95% CI, 0.26-0.51); primary education (β = 0.29; 95% CI, 0.17-0.41); O levels or equivalent education (β = 0.35; 95% CI, 0.21-0.50); A levels, polytechnic, diploma, or technical school equivalent (β = 0.27; 95% CI, 0.06-0.47); university education (β = 0.30; 95% CI, 0.07-0.52); BMI (β = −0.01; 95% CI −0.02 to 0.00); and baseline AMT score (β = −0.48; 95% CI, −0.51 to −0.45) were associated with change in AMT score (eTable 10 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}).

Discussion {#H1-4-ZOI200166}
==========

In this study, we observed a 6-year longitudinal association between presenting VI and poorer VA at baseline and decline in cognitive function. Evaluation of presenting VI reflects the habitual vision status of the elderly population. This association was particularly strong for individuals who were blind compared with individuals who had low vision (based on better eye; β = −1.07 vs −0.25). Furthermore, individuals who remained or became visually impaired over 6 years also experienced a greater magnitude of decline in cognitive function, further highlighting the importance of preserving good vision among elderly people. Among individuals with baseline VI and substantial cognitive decline, the leading causes of VI were undercorrected refractive error and cataract, 2 conditions that are easily treatable. To our knowledge, this was the first longitudinal, population-based study of a multiethnic Asian population that prospectively evaluated this association. Our findings may help to better identify elderly people who may be at higher risk for cognitive decline and reemphasize the importance of early detection and management of VI.

We compared our findings with those from other studies,^[@zoi200166r5],[@zoi200166r6],[@zoi200166r7],[@zoi200166r18],[@zoi200166r38]^ which were mostly conducted in Western populations. Similar to our findings, the Salisbury Eye Evaluation study^[@zoi200166r5]^ in the US reported that poorer presenting VA at baseline was independently associated with lower Mini-Mental State Examination scores during follow-up periods of 2 to 8 years. Likewise, several studies^[@zoi200166r6],[@zoi200166r7]^ observed increased odds of incident cognitive impairment among individuals with presenting VI at baseline. Specifically, Anstey et al^[@zoi200166r38]^ observed that VA decline in both eyes was associated with memory deterioration. The direction of our findings is similar to these studies,^[@zoi200166r5],[@zoi200166r6],[@zoi200166r7],[@zoi200166r18],[@zoi200166r38]^ thereby further supporting the association between VI and decline in cognitive function. Nevertheless, the Blue Mountains Eye Study in Australia reported that best-corrected VI (based on better or worse eye) had no association with cognitive deterioration during follow-up of 5 and 10 years.^[@zoi200166r18]^

Several mechanisms have been postulated to potentially explain the association between VI and decline in cognitive function. First, these 2 factors are strongly associated with aging.^[@zoi200166r39],[@zoi200166r40],[@zoi200166r41]^ Second, VI may be associated with the reduced frequency of daily activities and ability to perform brain-stimulating activities, such as reading and seeing faces,^[@zoi200166r8]^ thereby reducing cognitive ability because of a lack of sensory stimulus.^[@zoi200166r9],[@zoi200166r10],[@zoi200166r11],[@zoi200166r12],[@zoi200166r13]^ In this regard, previous studies^[@zoi200166r42],[@zoi200166r43]^ also found that vision-related interventions, such as the Useful Field of View training, may improve cognitive function among elderly individuals, further indicating the association between vision and cognitive function. Nonetheless, it remains unclear whether the observed association is a direct causal effect or one that is mediated by intermediate factors, such as reduced involvement in social and cognitively stimulating activities owing to VI. Thus, further studies are still required to investigate the potential mediation pathways in this association.

In our study, among individuals with VI at baseline and substantial cognitive decline over 6 years, we identified the leading causes of VI to be undercorrected refractive error and cataract, which are predominantly preventable or treatable. We also observed that individuals with baseline VI that improved to normal vision and those whose vision remained normal over 6 years had significantly lower magnitudes of decline in cognitive function. In this regard, previous studies also reported that cataract surgery with improved visual outcome was associated with improved cognitive performance^[@zoi200166r44],[@zoi200166r45]^ and with increased gray matter volume in the cortex.^[@zoi200166r45],[@zoi200166r46]^ Likewise, the Beijing Eye Study observed that individuals with appropriate refractive correction had higher cognitive scores than those without refractive correction.^[@zoi200166r47]^ These findings collectively suggest that the risk of cognitive decline may be ameliorated with appropriate and timely intervention of VI.

Strengths and Limitations {#H2-6-ZOI200166}
-------------------------

The strengths of this study include its large size and composition of the 3 major racial/ethnic groups in Asia. In addition, the long follow-up (6 years) of our study provides a unique opportunity to further elucidate the development of cognitive decline, which is a slow and progressive chronic condition. The comprehensive study design also allowed us to provide insights on the main causes of VI among individuals with cognitive decline. This information will be useful in formulating potential interventional strategies.

This study also has limitations. First, although the observed associations were statistically significant, the effect estimates were generally of small magnitude. Thus, the clinical application of our findings needs to be further validated in future studies. Second, the AMT is clinically classified as a screening test,^[@zoi200166r48]^ and its results primarily serve as a proxy for clinically diagnosed cognitive decline. Third, in our study, excluded individuals in general had different profiles compared with included individuals (eTable 1 in the [Supplement](#note-ZOI200166-1-s){ref-type="supplementary-material"}); thus, potential follow-up bias cannot be entirely ruled out in our sample. Fourth, despite adjusting for a range of potential confounders in our analysis, there might still be a residual confounding effect, particularly because of age and other factors that are associated with aging.

Conclusions {#H1-5-ZOI200166}
===========

This prospective, population-based cohort study of a multiethnic Asian population demonstrated that VI was associated with decline in cognitive function over 6 years. Most of these VI cases were attributable to undercorrected refractive error and cataract, which are highly preventable or treatable, therefore further emphasizing the importance of prompt interventions for VI. Holistic measures appear to be needed to manage preventable VI and to reduce the collective burden of both visual and cognitive decline.
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